EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.
Abstract | Background: Methods: High-throughput kinome analyses were performed in NF2-null human arachnoidal and meningioma cell lines to identify functional kinome changes upon NF2 loss. Immunoblotting confirmed the activation of kinases and demonstrated effectiveness of drugs to block the activation. Drugs, singly and in combination, were screened in cells for their growth inhibitory activity. Antitumor drug efficacy was tested in an orthotopic meningioma model. Results: Conclusion: Co-targeting mTORC1/2 and EPH RTK/SFK pathways could be a novel effective treatment strategy for NF2-deficient meningiomas.
|
Authors | Steven P Angus, Janet L Oblinger, Timothy J Stuhlmiller, Patrick A DeSouza, Roberta L Beauchamp, Luke Witt, Xin Chen, Justin T Jordan, Thomas S K Gilbert, Anat Stemmer-Rachamimov, James F Gusella, Scott R Plotkin, Stephen J Haggarty, Long-Sheng Chang, Gary L Johnson, Vijaya Ramesh, Children’s Tumor Foundation Synodos for NF2 Consortium |
Journal | Neuro-oncology
(Neuro Oncol)
Vol. 20
Issue 9
Pg. 1185-1196
(08 02 2018)
ISSN: 1523-5866 [Electronic] England |
PMID | 29982664
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- Antineoplastic Agents
- Biomarkers, Tumor
- NF2 protein, human
- Neurofibromin 2
- Receptors, Eph Family
|
Topics |
- Animals
- Antineoplastic Agents
(pharmacology)
- Apoptosis
- Biomarkers, Tumor
(antagonists & inhibitors)
- Cell Proliferation
- Gene Expression Regulation, Neoplastic
(drug effects)
- Humans
- Meningeal Neoplasms
(drug therapy, metabolism, pathology)
- Meningioma
(drug therapy, metabolism, pathology)
- Mice
- Mice, Inbred NOD
- Mice, SCID
- Neurofibromin 2
(deficiency)
- Receptors, Eph Family
(antagonists & inhibitors, genetics, metabolism)
- Tumor Cells, Cultured
- Xenograft Model Antitumor Assays
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|